Beacon Therapeutics gives first doses of AGTC-501 in VISTA trial

Retrieved on: 2024-06-17 15:31:02

Tags for this article:

Click the tags to see associated articles and topics

Beacon Therapeutics gives first doses of AGTC-501 in VISTA trial. View article details on hiswai:

Excerpt

AGTC-501 is highly anticipated as it could become the first gene therapy specifically indicated for X-linked retinitis pigmentosa.

Article found on: www.pharmaceutical-technology.com